//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
Reston, VA


Online Registration is Open!
Register by Friday, August 21, 2015 to Save up to $300.
» View Pricing

Download Brochure

Add to Outlook Calendar

Stay Connected

Join IBC Life Sciences' LinkedIn Group: "BioProcessing Professionals"

Follow @ibcusa on Twitter for special offers and news about the event.

Connect on Facebook

Add the event to your calendar by selecting "Join" on the event page

Immunogenicity for Biotherapeutics


From Concept to Approval: De-Risking and Predicting Immune Responses for Complex Molecules

November 09-10, 2015 · Hyatt Regency Reston · Reston, VA

Alt Language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese
  • English

Event Overview

Event Overview

As the longest and most comprehensive event on predicting and de-risking immune responses from concept to product, the 16th annual Immunogenicity for Biotherapeutics event delivers key insights and case studies to remove the uncertainty surrounding immune response prediction and minimization. With strategies to overcome immunogenicity challenges from pre-clinical and development all the way through post-clinical stages, this event is a "can't miss" to create reliable, predictable, and worthwhile tests to improve biologic safety.

Key Benefits Include:

  • Exclusive access to senior FDA and industry experts, offering unmatched state-of-the-art insight from both technical and regulatory perspectives.
  • Strategies and case studies to help understand, anticipate, and mitigate the risks of immunogenicity from concept to product
  • Create and capitalize on the most advanced transgenic animal models to get the best grasp on predicting immunogenicity
  • Identify the must-have features of molecular design to minimize or eliminate epitopes
  • Adapt your skills to the unique features of newly-developed varieties of biomolecules, including biosimilars, nanomedicines, bispecifics and antibody-drug conjugates
  • Insights from industry thought leaders on managing and reducing off-target toxicity concerns with antibody-drug conjugates and other protein therapeutics
  • Updates on higher-order structure techniques and assessment to improve the safety of therapeutic candidates

"I was particularly impressed by this event's extremely high standards for speakers, panel discussions, networking and audience feedback." - Harald Kropshofer, Senior Personalized Healthcare Leader, F. Hoffman La Roche AG

Who Should Attend

Hear from industry leaders and meet with Senior Scientists, Research Scientists, Principal Scientists, Directors and CSO from pharmaceutical and biotech, and other specialists in the following departments:

  • Antibody Engineering
  • Assay Development
  • Bioanalytical Method Development
  • Bioanalytical Research
  • Biologic Research
  • Drug safety
  • Immunoassays
  • Immunochemistry
  • Immunology
  • Immunotherapeutics
  • Pharmacokinetics/ Pharmacodynamics
  • Protein Biochemistry
  • Therapeutic Protein

"An excellent program - extremely useful from a technical perspective. The lessons from the case studies and discussions will assist our group's development efforts." - Thomas Klem, Scientist, Shire

Co-Located with: IBC's 19th Annual
Well Characterized Biologicals

This meeting provides the regulatory guidance and analytical characterization strategies you need to ensure accurate CMC submissions. For nearly two decades, this case-study driven event has led the industry by consistently providing the latest updates on the most novel bioanalytical methods for sound characterization of biologics. » Learn More